CN1548036A - Medicine containing acarnine compound as active component - Google Patents
Medicine containing acarnine compound as active component Download PDFInfo
- Publication number
- CN1548036A CN1548036A CNA031287425A CN03128742A CN1548036A CN 1548036 A CN1548036 A CN 1548036A CN A031287425 A CNA031287425 A CN A031287425A CN 03128742 A CN03128742 A CN 03128742A CN 1548036 A CN1548036 A CN 1548036A
- Authority
- CN
- China
- Prior art keywords
- medicine
- compound
- human body
- alkannin
- kaning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 150000001875 compounds Chemical class 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims description 12
- 201000011510 cancer Diseases 0.000 claims abstract description 4
- -1 alkannin compound Chemical class 0.000 claims description 42
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 claims description 40
- 239000004229 Alkannin Substances 0.000 claims description 39
- 235000019232 alkannin Nutrition 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 9
- 208000032843 Hemorrhage Diseases 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 241000222122 Candida albicans Species 0.000 claims description 4
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 4
- 206010012504 Dermatophytosis Diseases 0.000 claims description 4
- 241001460074 Microsporum distortum Species 0.000 claims description 4
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 4
- 208000002474 Tinea Diseases 0.000 claims description 4
- 244000000010 microbial pathogen Species 0.000 claims description 4
- 206010007134 Candida infections Diseases 0.000 claims description 3
- 241000590002 Helicobacter pylori Species 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 3
- 201000003984 candidiasis Diseases 0.000 claims description 3
- 229940037467 helicobacter pylori Drugs 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 206010028470 Mycoplasma infections Diseases 0.000 claims description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 241000202921 Ureaplasma urealyticum Species 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 229940045505 klebsiella pneumoniae Drugs 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000006268 Sarcoma 180 Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 4
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 22
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 16
- 238000012360 testing method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 8
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical class C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241001071917 Lithospermum Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000607715 Serratia marcescens Species 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 241001050829 Arnebia guttata Species 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000235645 Pichia kudriavzevii Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- WNFXUXZJJKTDOZ-HNNXBMFYSA-N [(1s)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] acetate Chemical compound C1=CC(O)=C2C(=O)C([C@@H](OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-HNNXBMFYSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- WNFXUXZJJKTDOZ-UHFFFAOYSA-N shikonin acetate Natural products C1=CC(O)=C2C(=O)C(C(OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- BATBOVZTQBLKIL-KRWDZBQOSA-N Alkannin beta,beta-dimethylacrylate Chemical compound C1=CC(O)=C2C(=O)C([C@@H](OC(=O)C=C(C)C)CC=C(C)C)=CC(=O)C2=C1O BATBOVZTQBLKIL-KRWDZBQOSA-N 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000130784 Arnebia euchroma Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 101710142246 External core antigen Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001442052 Symphytum Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010047097 Vascular purpura Diseases 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- MXANJRGHSFELEJ-UHFFFAOYSA-N beta:-hydroxy isovaleryl shikonin Natural products C1=CC(O)=C2C(=O)C(C(OC(=O)CC(C)(C)O)CC=C(C)C)=CC(=O)C2=C1O MXANJRGHSFELEJ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 201000009862 superficial mycosis Diseases 0.000 description 1
- 206010052366 systemic mycosis Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention is medicine containing acarnine compound or its salt, and the medicine is used in preventing and treating human microbial infectious diseases, inflammatory diseases, malignant tumor, hemorrhagic disease, hematopathy and immunological diseases.
Description
Technical field the present invention relates to contain the medicine of A Kaning (Alkannin) compounds or its salt, relates in particular to contain alkannin compound or its salt are used to prevent and treat the infected by microbes (containing SARA), inflammation, tumor of human body, hemorrhage, hematopathy or immune regulative disease as active component medicine.
The background technology alkannin compound is disclosed chemical compound in the bibliographical information (Xiao Peigen, Jia Xiaoguang etc. edit " Radix Arnebiae (Radix Lithospermi) ", the calendar year 2001 version P24-25 of China Traditional Chinese Medicine Publishing House), and wherein alkannin compound has following formula:
Alkannin compound is all water insoluble, and being soluble in oil, alcohol or ethers, it can obtain by extracting in comfrey such as Radix Arnebiae (Radix Lithospermi) (Lithospermun erythrorhizon Sieb.et Zucc.), lithospermum euchromum Royle (Arnebia euchroma (Royle) Johnst.), the arnebia guttata Bunge (Arnebiaguttata Bunge.) etc.The mixed extract of known Radix Arnebiae (Radix Lithospermi) has the effect of anti-inflammatory etc., but, when medication, all be to use with the form of mixed extract, about will be from the mixed extract of plant Radix Arnebiae (Radix Lithospermi) isolating alkannin compound and artificial and biosynthesis alkannin compound be used for pharmacy with independent a kind of chemical compound or a few combination of compounds, yet there are no report in the preparation especially for medicines such as the infected by microbes of prevention and treatment human body, inflammation, tumor, hemorrhage, hematopathy or immune regulative diseases.
Therefore summary of the invention the object of the present invention is to provide the medicine of a kind of infected by microbes that is used to prevent and treat human body by isolated independent a kind of chemical compound or a few compound from Radix Arnebiae extract, inflammation, tumor, hemorrhage, hematopathy or immune regulative disease.
The invention provides the medicine of the infected by microbes that is used to prevent and treat human body, inflammation, tumor, hemorrhage, hematopathy or immune regulative disease, this medicine contains alkannin compound or its esters as shown in the formula (I) expression,
When R is for OH in the formula be:
A Kaning (Alkannin);
R is (CH
3)
2C=CHC (O) during O-is:
β, and beta-dimethyl-acry-lalkannin (β, β-dimethylacrylalkannin);
R is CH
3C (O) during O-is:
Acetyl A Kaning (acetylalkannin);
R is (CH
3)
2C=C (CH
3) CH
2C (O) during O-is:
2,3-dimethyl pentene acyl A Kaning (teracrylalkannin);
R is (CH
3)
2COHCH
2C (O) during O-is:
Beta-hydroxy isovaleryl A Kaning (β-hydroxyisovalerylalkannin):
R is (CH
3)
2C[OC (O) CH
3] CH
2C (O) during O-is:
β-acetoxyl group isovaleryl A Kaning (β-acetoxyisovalerylalkannin):
Any 1-5 kind combination in the above-claimed cpd; Wherein: preferably contain A Kaning, β, the 1-3 kind among beta-dimethyl-acry-lalkannin and the acetyl A Kaning; More preferably contain β, beta-dimethyl-acry-lalkannin and/or acetyl A Kaning; Most preferably contain acetyl A Kaning.The salt of alkannin compound of the present invention comprises alkali metal, alkaline-earth metal and ammonium salt etc.
Medicine of the present invention can contain any independent a kind of chemical compound in the alkannin compound as crude drug, also can contain its a few combination of compounds, wherein the purity of each independent chemical compound is more than 80% or 80%, and preferred purity is more than 90% or 90%.When containing its a few combination of compounds, the content of effective in this a few compound compositions is more than 70% or 70%.
As required, medicine of the present invention can also contain other medicines as active component.There is no particular limitation for described other medicines, and those skilled in the art can suitably select according to the knowledge of prior art.
The content range of the alkannin compound that contains in the medicine of the present invention can suitably be selected according to different preparations and disease at 0.0001%-75% (percentage by weight).When being used for human body, the day use amount of described alkannin compound can be controlled between the 10 μ g-20g, preferred 100 μ g-10g, more preferably 1mg-8 gram, most preferably 5 grams.Can suitably select according to patient's different situations such as age, body weight, the state of an illness etc.Can single or use several times.Medicine of the present invention can be with the mode administration of for oral administration, external, injection, suction or transdermal.
The medicine that contains alkannin compound of the present invention can be used for preventing and treating the infected by microbes of human body, and this microorganism comprises, pathogenic gram-positive cocci such as staphylococcus aureus, streptococcus pneumoniae, staphylococcus epidermidis, enterococcus faecalis etc.; Pathogenic Gram-negative coccus such as Klebsiella Pneumoniae, serratia marcescens, have a liking for Fructus Hordei Germinatus bacillus etc.; Anaerobism or little aerobic pathogenic bacterium are as helicobacter pylori etc.; Deep and superficial mycosis class such as candidiasis, Aspergillus fumigatus, cryptococcus, dermatophytosis, Candida krusei, most advanced and sophisticated many spores of match mycete etc.; Various mycoplasma infections such as Ureaplasma urealyticum, mycoplasma pneumoniae etc.; Viral and the pathogenic microorganism that causes the SARS disease of virus as hepatitis B virus, influenza virus, herpesvirus, HIV, as: coronavirus and variant viral thereof etc.
The medicine that contains alkannin compound of the present invention is to the pathogenic microorganism sensitivity, but insensitive to human body beneficial's microorganism such as lactobacillus, bacillus bifidus etc.
The medicine that contains alkannin compound of the present invention can be used for preventing and treating the inflammation of human body.This inflammation comprises, for example, and phlebitis, vascular purpura, vaginitis, edema etc.
The medicine that contains alkannin compound of the present invention also can be used for preventing and treating the hemorrhage and hematopathy of human body, for example empyrosis, various dermatitis, septicemia, hemophilia, primary thrombocytosis, leukemia etc.
The medicine that contains alkannin compound of the present invention also can be used for preventing and treating the tumor, particularly malignant tumor of human body, for example ascites tumor: hepatocarcinoma, L1210; Solid tumor: W256, S180, gastric cancer 823, scale cancer 109, Lewis lung cancer etc.
The medicine that contains alkannin compound of the present invention can be used for preventing and treating the immune regulative disease of human body, can promote body nonspecific immunity and specific immunization of cell by effects such as the lymphocytic immunne response of promotion T.
Therefore, medicine of the present invention can be used for respiratory system, digestive system, urinary system, reproductive system, blood system, blood circulation and skin and the mucosal sites of human body.
Below the specific embodiment preparation and the pharmacodynamics test that contains the pharmaceutical preparation of alkannin compound of the present invention is described in detail, but content of the present invention also not exclusively is confined to this.
Preparation example 1
After 2 kilograms of pulverizing of lithospermum euchromum Royle, colourless with Petroleum ether extraction to the Radix Arnebiae (Radix Lithospermi) residue, reclaim solvent and obtain 80 gram kermesinus slurries.The slurry of gained is separated preparation through the silica gel H column liquid chromatographic, that is:, obtain the monomer of 6 kinds of alkannin compounds noted earlier respectively with 1%-20% ethyl acetate-petroleum ether gradient elution.That is: 0.712 Ke Akaning (yield 0.89%), 29.024 restrains β, beta-dimethyl-acry-lalkannin (yield 36.28%), 13.27 gram acetyl A Kaning (yield 16.59%), 6.032 grams 2,3-dimethyl pentene acyl A Kaning (yield 7.54%), 0.776 gram beta-hydroxy isovaleryl A Kaning (yield 0.97%), 0.792 gram β-acetoxyl group isovaleryl A Kaning (yield 0.99%).Through high pressure liquid chromatographic analysis, purity is all more than 90%.
Preparation example 2.
After 2 kilograms of pulverizing of lithospermum euchromum Royle, cross the 20-40 mesh sieve, use CO
2-supercritical extraction obtains red paste 70 grams, separates preparation, preparative column: silica gel H 10 μ m 50 * 300mm by high-pressure liquid phase preparative hplc (German Knauer K1001 type); That is: with 1%-20% ethyl acetate-petroleum ether gradient elution, obtain the red monomer of foregoing 6 kinds of alkannin compounds respectively.That is: 0.707 Ke Akaning (yield 1.01%), 30.877 restrains β, beta-dimethyl-acry-lalkannin (yield 44.11%), 15.869 gram acetyl A Kaning (yield 22.67%), 6.034 grams 2,3-dimethyl pentene acyl A Kaning (yield 8.62%), 0.91 gram beta-hydroxy isovaleryl A Kaning (yield 1.30%) and 0.77 gram β-acetoxyl group isovaleryl A Kaning (yield 1.10%), through high pressure liquid chromatographic analysis, purity is all more than 90%.
Embodiment 1
Prepare the tablet of independent a kind of in described 6 kinds of chemical compounds or a few combination according to the method for well known to a person skilled in the art, wherein can be made into according to actual needs in the tablet and contain the 10%-70% alkannin compound.
Under aseptic operating condition, get acetyl A Kaning (acetylalkannin), 100 gram microcrystalline celluloses, 30 gram magnesium stearate, 4 gram hydroxypropyl methylcellulose that 100 grams obtain by above-mentioned preparation example 1 or preparation example 2.Make the tablet of 0.5 gram according to known tabletting technology and equipment.
Embodiment 2
Get the compositions (A Kaning, β, the mixing ratio of beta-dimethyl-acry-lalkannin and acetyl A Kaning be 1: 1: 2) of 100 grams by the alkannin compound of above-mentioned preparation example 1 or preparation example 2 acquisitions, other is identical with embodiment 1, the tablet of preparation 0.5 gram.
Embodiment 3
The unguentum for preparing described 6 kinds of alkannin compounds according to the method for well known to a person skilled in the art.Wherein can be made into according to actual needs in the unguentum and contain the 0.0001%-10% alkannin compound.Under aseptic technique, get alkannin compound (A Kaning, β that 0.5 above-mentioned preparation example 1 of gram or preparation example 2 obtain, the mixing ratio of beta-dimethyl-acry-lalkannin, acetyl Ah card peace beta-hydroxy isovaleryl A Kaning is 0.7: 1: 1: 2: 0.5), 80 the gram vaseline, 10 the gram liquid paraffin and 10 the gram anhydrous lanolins, in mortar, grind well, product is made in packing, is used for external.Also can use this unguentum, make paster according to the method for well known to a person skilled in the art and be used for Transdermal absorption.
Embodiment 4
The injection for preparing described 6 kinds of alkannin compounds according to the method for well known to a person skilled in the art.Under aseptic technique, get the β that 0.5 above-mentioned preparation example 1 of gram or preparation example 2 obtain, 15 milliliters of beta-dimethyl-acry-lalkannin, 400 milliliters of propylene glycol, 100 milliliters of ethanol, 20 milliliters of tween 80s, benzyl alcohol, mixture is fully dissolved, add water to 1000 milliliters, behind the mix homogeneously, injection products is made in bottling.
The test of pesticide effectiveness result of the medicine that contains alkannin compound is described below.
(1) preparation of medicine
Take by weighing the A Kaning, the β that obtain in 5.0 milligrams preparation example 1 or the preparation example 2 respectively, beta-dimethyl-acry-lalkannin and acetyl A Kaning.Medicine is dissolved among 1 milliliter of DMSO.With the RPMI-1640 culture medium with 50 times of its dilutions after, packing, and further be diluted to concentration and be respectively 100,50,25,12.5,6.25,3.125,1.5625,0.78125,0.390625 (μ g/ml).
(2) sensitivity tests of medicine
The medicine branch of above-mentioned each concentration is installed in the orifice plate, and be about 10 with the bacteria concentration for preparing
3-10
6Each inoculation.
Result of the test shows: A Kaning, β, and beta-dimethyl-acry-lalkannin and acetyl A Kaning have suitable sensitivity to gram-positive golden yellow coccus, and its sensitivity range (MIC) is 0.391-12.5 μ g/ml; To common gram negative pathogenic bacteria, its sensitivity of Klebsiella pneumonia MIC scope is 0.391-6.25 μ g/ml, and the minority bacterial strain is 12.5-50 μ g/ml; Serratia marcescens (most of clinical separation strain) and have a liking for its most bacterial strain sensitivity ranges of Fructus Hordei Germinatus bacillus at 0.391-3.125 μ g/ml.Wherein especially effective to having a liking for the Fructus Hordei Germinatus bacillus, its sensitivity range is 0.391-0.781 μ g/ml, and berberine is 8-32 μ g/ml,, obviously is better than berberine that is; MIC to bacteroid especially bacteroides fragilis is 0.391-6.25 μ g/ml; Quite responsive to helicobacter pylori, its MIC is 0.391-0.781 μ g/ml.
In addition, β, the result of the external antifungal test of beta-dimethyl-acry-lalkannin shows: to candidiasis and cryptococcal MIC scope between 2.08-33.3 μ g/ml, MIC
90Be 33.3 μ g/ml, and the MIC scope of fluconazol is between 0.125-64 μ g/ml, MIC
90Be 69 μ g/ml; To the MIC scope of dermatophytosis between 4.16-8.32 μ g/ml, MIC
90Be 4.16 μ g/ml, and fluconazol to the MIC scope of most of bacterial strains of dermatophytosis between 32-64 μ g/ml, MIC
90Be 64 μ g/ml, both obvious differences.In addition, amazingly be, β, beta-dimethyl-acry-lalkannin has for the drug-fast Candida krusei of fluconazol and suppresses effect preferably, MIC is 8.32-16.6 μ g/ml, and matches the mould MIC of many spores between 4.16-8.32 μ g/ml for all insensitive tip of most antifungal drugs such as fluconazol.Acetyl A Kaning is 3.90625 μ g/ml to the MIC of Cryptococcus histolyticus in addition, is 0.90625-62.5 μ g/ml to the MIC of hungmao mentagrophyte; β, beta-dimethyl-acry-lalkannin is 3.0625-250 μ g/ml to the MIC of Aspergillus fumigatus, cryptococcus and hungmao mentagrophyte.Therefore, alkannin compound is the potent antifungal agent of a kind of wide spectrum.
In addition, alkannin compound of the present invention to the MIC of human body beneficial's microorganism such as lactobacillus and bacillus bifidus all more than 200 μ g/ml, therefore,, but insensitive by the above-mentioned data medicine that contains alkannin compound of the present invention as can be seen to human body beneficial's microorganism to the pathogenic microorganism sensitivity.
From the contrast test of the mixed extract of Radix Arnebiae (Radix Lithospermi) and the described alkannin compound of 1-3 kind as can be seen, it is as shown in table 1 that the medicine of the described alkannin compound of the 1-3 of containing kind of the present invention obviously is better than the result of its MIC of mixed extract (μ g/ml) of Radix Arnebiae (Radix Lithospermi).
Table 1
| Strain name | ????A | ????B | ????C |
| Staphylococcus epidermidis | ????12.5 | ????0.391 | ????0.7812 |
| Serratia marcescens | ????25 | ????0.781 | ????3.125 |
| Bacteroid | ????＞200 | ????0.391 | ????0.391 |
| Candida albicans | ????500 | ????3.9062 | ????250 |
Annotate: A is the mixed extract of Radix Arnebiae (Radix Lithospermi);
B is β, beta-dimethyl-acry-lalkannin;
C is the mixture (A Kaning, β, the mixing ratio of beta-dimethyl-acry-lalkannin and acetyl A Kaning is 1: 1: 2) of alkannin compound
A Kaning, β, beta-dimethyl-acry-lalkannin and acetyl A Kaning show the result of the fungistatic effect test of mycoplasma pneumoniae, its minimum concentration MIC that suppresses mycoplasma pneumoniae is respectively, 3.751 μ g/ml, 2 μ g/ml and 7.819 μ g/ml are equivalent to the inhibition effect of pure injection erythromycin 0.1925 μ g/ml.
Unguentum with the alkannin compound of the foregoing description 3 preparation carries out the external preparation for skin medicine to shown in the following tabulation 2 of result of the test of part disease.
Table 2
| Disease | Experimenter's number | Effective percentage | Cure rate | The treatment natural law | Route of administration | Remarks |
| Empyrosis | ??300 | ??100％ | ??100％ | ??6-20 | Affected part is directly given | Scald shallow 2 degree 186 people of 92 people, dark 2 and 3 degree 114 people |
| Hemorrhoid | ??117 | ??100％ | ??97.4％ | ??15 | Affected part is directly given | Three examples recurred after half a year |
| Herpes zoster | ??98 | ??100％ | ??100％ | ??3-7 | Affected part is directly given | Wherein 12 examples add and use polyinosini |
| Cervical erosion | ??80 | ??100％ | ??100％ | ??10-20 | Vagina administration | |
| Children's's nose bleeding | ??257 | ??99.6％ | ??72.8％ | ??15 | Nasal-cavity administration | |
| Verruca plana | ??100 | ??96％ | ??81％ | ??10-30 | Affected part is directly given | |
| Chronic prostatitis | ??40 | ??82.5％ | ??57.5％ | ??10-20 | Anum administration | |
| Acne | ??50 | ??92％ | ??60％ | ??15 | Affected part is directly given | |
| Decubital ulcer | ??30 | ??100％ | ??100％ | ??7-21 | Affected part is directly given | |
| Eczema rhagadiforme | ??98 | ??94.9％ | ??66.3％ | ??10-30 | Affected part is directly given | |
| Condyloma acuminatum | ??55 | ??100％ | ??100％ | ??5-35 | Affected part is directly given | |
| Baby napkin dermatitis | ??208 | ??100％ | ??100％ | ??2-6 | Affected part is directly given |
As can be seen from the above table, the external preparation for skin medicine of alkannin compound is suitable for treating most abscess skin ulcer scabies, herpes, and is especially remarkable to burn and scald effect, do not stay cicatrix after healing.
A Kaning, β, beta-dimethyl-acry-lalkannin and acetyl A Kaning are to shown in the following tabulation 3 of animal test results of transplantation tumor.
Table 3
| Tumor type | β, beta-dimethyl-acry-lalkannin | Acetyl A Kaning | A Kaning | |||
| Tumour inhibiting rate | Increase in life span | Tumour inhibiting rate | Increase in life span | Tumour inhibiting rate | Increase in life span | |
| Ascitic type liver cancer | ??113.4％ | ??112.6％ | ??130.8％ | |||
| ??S180 | ??9.63％ | ??35.7％ | ||||
| Lewis lung cancer | ??42.8％ | ??52.6％ | ||||
| ??L1210 | ??128％ | |||||
| ??W256 | ??77％ | |||||
As can be seen from the above table, β, beta-dimethyl-acry-lalkannin has in various degree curative effect to hepatocarcinoma, S180, Lewis lung cancer; Acetyl A Kaning has in various degree curative effect to hepatocarcinoma, S180, L1210, Lewis lung cancer, W256; A Kaning is only effective to hepatocarcinoma.
Alkannin compound shows the result of the test of virus: the 7th day oral β behind the dhbv dna infected duck, beta-dimethyl-acry-lalkannin, 100mg/kg one day 2 times, 10 days to the inhibition effect of infected duck serum DHBV-DNA level significantly (P＜0.05-0.01), non-toxic reaction; The 50mg/kg group has significant inhibitory effect (P＜0.05).
β, beta-dimethyl-acry-lalkannin show that to the in vitro tests of hepatitis B virus concentration is 30 μ g/ml, are 96.2601% to the average suppression ratio of HBsAg, are 91.6056% to the average suppression ratio of HBeAg.
Ah card's peace β, the result of the test of external anti-HIV-1 reverse transcriptase of beta-dimethyl-acry-lalkannin and intergrase is as shown in table 4 below.
Table 4
| ????IC 50(μg/ml) | ||
| Anti-hiv reverse transcriptase | Positive control PFA | ????0.097 |
| Alkannin compound | ????＞20 | |
| Anti-hiv integrase | Positive control ABPS-Y | ????0.922 |
| Alkannin compound | ????12.467 |
With ametycin induced mice immunologic hypofunction model, the effect of research alkannin compound.The result shows the β of lumbar injection 6mg/kg every day, beta-dimethyl-acry-lalkannin, continuous 5 days, mouse boosting cell NK cell poison improves about 20% (P＜0.001), shown to make macrophage injury recovery to some extent in the mouse peritoneal, can increase intraperitoneal macrophage migration ability, increased the lymphocytic activity of T, and can promote the lymphocytic immunne response effect of T, have the body nonspecific immunity of promotion and specific immunization of cell.
Claims (13)
1. medicine that is used to prevent and treat human microorganism's infection, inflammation, tumor, hemorrhage, hematopathy or immune regulative disease, this medicine contains the alkannin compound or its esters of formula (I) expression,
R is for being selected from by OH, (CH in the formula
3)
2C=CHC (O) O-, CH
3C (O) O-, (CH
3)
2C=C (CH
3) CH
2C (O) O-, (CH
3)
2COHCH
2C (O) O-, (CH
3)
2C[OC (O) CH
3] CH
2Any 1-5 kind in C (O) group that O-formed.
2. medicine as claimed in claim 1, wherein R is for being selected from OH, (CH
3)
2C=CHC (O) O-and CH
3The 1-3 kind of C (O) O-.
3. medicine as claimed in claim 2, wherein R is (CH
3)
2C=CHC (O) O-and/or CH
3C (O) O-.
4. medicine as claimed in claim 3, wherein R is (CH
3)
2C=CHC (O) O-.
5. medicine as claimed in claim 1, the purity of each chemical compound that wherein said medicine contains are more than 80% or 80%.
6. medicine as claimed in claim 1, the purity of each chemical compound that wherein said medicine contains are more than 90% or 90%.
7. medicine as claimed in claim 1, wherein when described medicine contained several combination of compounds, the content of effective in the said composition was more than 70% or 70%
8. medicine as claimed in claim 1, this medicine also can contain the other medicines active component.
9. medicine as claimed in claim 1, when being used for human body, the day use amount of described alkannin compound can be controlled between the 10 μ g-10g.
10. medicine as claimed in claim 1 can be with the mode administration of for oral administration, external, injection, suction or transdermal.
11. medicine as claimed in claim 1, this medicine is used for the treatment of or prevents the infected by microbes of each system of human body, comprises streptococcus pneumoniae, Klebsiella Pneumoniae, helicobacter pylori, candidiasis, cryptococcus, dermatophytosis, most advanced and sophisticated many spores of match mycete; Various mycoplasma infections comprise Ureaplasma urealyticum, mycoplasma pneumoniae; Or viral infection comprises hepatitis B virus, influenza virus, herpesvirus, HIV virus.
12. medicine as claimed in claim 1, this medicine are used for the treatment of or prevent the pathogenic microorganism that may cause the SARS disease of human body, as: coronavirus and variant viral thereof, negative myxovirus, chlamydia etc.
13. medicine as claimed in claim 1, this medicine are used for the treatment of or prevent ascites tumor, hepatocarcinoma, L1210, solid tumor, W256, sarcoma 180, gastric cancer 823, scale cancer 109 or the Lewis lung cancer of human body.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810098095XA CN101288665A (en) | 2003-05-08 | 2003-05-08 | Medicine containing alkannin compound as active component |
| CNB031287425A CN100455283C (en) | 2003-05-08 | 2003-05-08 | Medicine containing acarnine compound as active component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031287425A CN100455283C (en) | 2003-05-08 | 2003-05-08 | Medicine containing acarnine compound as active component |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810098095XA Division CN101288665A (en) | 2003-05-08 | 2003-05-08 | Medicine containing alkannin compound as active component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1548036A true CN1548036A (en) | 2004-11-24 |
| CN100455283C CN100455283C (en) | 2009-01-28 |
Family
ID=34322233
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810098095XA Pending CN101288665A (en) | 2003-05-08 | 2003-05-08 | Medicine containing alkannin compound as active component |
| CNB031287425A Expired - Lifetime CN100455283C (en) | 2003-05-08 | 2003-05-08 | Medicine containing acarnine compound as active component |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810098095XA Pending CN101288665A (en) | 2003-05-08 | 2003-05-08 | Medicine containing alkannin compound as active component |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN101288665A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1307987C (en) * | 2005-07-25 | 2007-04-04 | 北京羚锐伟业科技有限公司 | New usage of alkannin |
| US7622506B2 (en) | 2006-04-07 | 2009-11-24 | Sunten Phytotech Co., Ltd. | Naphthalenedione compounds for treating inflammation related disorders and microbial infection |
| CN102198130A (en) * | 2011-03-30 | 2011-09-28 | 中国人民解放军第二军医大学 | Use of shikonin as antifungal medicine synergist |
| CN102198124A (en) * | 2010-03-26 | 2011-09-28 | 山东靶点药物研究有限公司 | Gromwell extract for treating rheumatoid arthritis, and soft capsules thereof |
| CN103919758A (en) * | 2010-03-26 | 2014-07-16 | 苏州雷纳药物研发有限公司 | Medical application of gromwell naphthaquinone compounds |
| CN105622374A (en) * | 2016-03-02 | 2016-06-01 | 山东省分析测试中心 | Method for separating and preparing compound with neuraminidase inhibitory activity from radix lithospermi |
| CN106924323A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the radix macrotomiae in the medicine for preparing treatment virus B hepatitis |
| CN110269852A (en) * | 2019-08-07 | 2019-09-24 | 中美（河南）荷美尔肿瘤研究院 | β, beta-dimethyl-acry-lalkannin application in preparation of anti-tumor drugs |
| CN115381778A (en) * | 2022-08-29 | 2022-11-25 | 成都紫旺药业有限责任公司 | Lithospermum naphthoquinone water-soluble solid dispersion, water-soluble preparation and preparation method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1165509C (en) * | 2002-03-19 | 2004-09-08 | 中山大学 | Gronwell naphthaquinone derivative and its application in preparing anticancer medicine |
-
2003
- 2003-05-08 CN CNA200810098095XA patent/CN101288665A/en active Pending
- 2003-05-08 CN CNB031287425A patent/CN100455283C/en not_active Expired - Lifetime
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1307987C (en) * | 2005-07-25 | 2007-04-04 | 北京羚锐伟业科技有限公司 | New usage of alkannin |
| US7622506B2 (en) | 2006-04-07 | 2009-11-24 | Sunten Phytotech Co., Ltd. | Naphthalenedione compounds for treating inflammation related disorders and microbial infection |
| CN102198124B (en) * | 2010-03-26 | 2014-10-29 | 山东靶点药物研究有限公司 | Gromwell extract for treating rheumatoid arthritis, and soft capsules thereof |
| CN102198124A (en) * | 2010-03-26 | 2011-09-28 | 山东靶点药物研究有限公司 | Gromwell extract for treating rheumatoid arthritis, and soft capsules thereof |
| CN103919758A (en) * | 2010-03-26 | 2014-07-16 | 苏州雷纳药物研发有限公司 | Medical application of gromwell naphthaquinone compounds |
| CN103919758B (en) * | 2010-03-26 | 2015-11-25 | 苏州雷纳药物研发有限公司 | The medical usage of alkannin derivatives |
| CN102198130B (en) * | 2011-03-30 | 2012-08-29 | 中国人民解放军第二军医大学 | Use of shikonin as antifungal medicine synergist |
| CN102198130A (en) * | 2011-03-30 | 2011-09-28 | 中国人民解放军第二军医大学 | Use of shikonin as antifungal medicine synergist |
| CN106924323A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the radix macrotomiae in the medicine for preparing treatment virus B hepatitis |
| CN105622374A (en) * | 2016-03-02 | 2016-06-01 | 山东省分析测试中心 | Method for separating and preparing compound with neuraminidase inhibitory activity from radix lithospermi |
| CN105622374B (en) * | 2016-03-02 | 2018-04-17 | 山东省分析测试中心 | A kind of method that separation prepares the compound with neuraminic acid enzyme inhibition activity from Asian puccoon |
| CN110269852A (en) * | 2019-08-07 | 2019-09-24 | 中美（河南）荷美尔肿瘤研究院 | β, beta-dimethyl-acry-lalkannin application in preparation of anti-tumor drugs |
| CN115381778A (en) * | 2022-08-29 | 2022-11-25 | 成都紫旺药业有限责任公司 | Lithospermum naphthoquinone water-soluble solid dispersion, water-soluble preparation and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100455283C (en) | 2009-01-28 |
| CN101288665A (en) | 2008-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Choi et al. | Aqueous extract isolated from Platycodon grandiflorum elicits the release of nitric oxide and tumor necrosis factor-α from murine macrophages | |
| CN100370976C (en) | Medicine containing shikonin compound as active component | |
| CN100455283C (en) | Medicine containing acarnine compound as active component | |
| Wang et al. | A comprehensive review on pharmacological, toxicity, and pharmacokinetic properties of phillygenin: Current landscape and future perspectives | |
| CN1253464C (en) | Ansi glycoside compound and its medicinal composition, preparation and use | |
| CN1251698C (en) | Plant extract and compound for treating endotoxin blood disease, and its extraction method and application | |
| CN1286455C (en) | Pharmaceutical use of 5-hydroxymethyl furfural | |
| CN1217669C (en) | Naringin used in preparing medicine for curing acute and chronic bronchitis | |
| CN1238357C (en) | Hypoxylonin and its preparation method and application | |
| WO2022262241A1 (en) | Forsythia suspensa leaf extract and use thereof for increasing abundance of akk in intestinal tracts | |
| CN103833823A (en) | Diterpene dimer compounds and pharmaceutical compositions and preparation method and application thereof | |
| CN1506067A (en) | Application of chitin oligose in anticancer drug | |
| CN1939327A (en) | Pharmaceutical usage of neolinarin, linarin and their composition | |
| CN1289505C (en) | New compound,its preparation method, medicine preparation using said compound as active component, its action and application | |
| CN1305479C (en) | Low polarity ginsenoside combination possessing anti-tumor activity | |
| CN101037466A (en) | Steroid saponins and preparation method and application | |
| CN106135204A (en) | In Psidium plant, Benzophenones compound is as antimycotic application | |
| CN1958597A (en) | Triterpene saponin compound of cycro jackfruit alkyl, and effect for anti tumor | |
| CN1386499A (en) | Application of diphenylvinyl phenol glucosides in preparing hypolipemic medicine | |
| CN110452278A (en) | Smelly seven secondary metabolites and preparation method thereof and its application in pharmacy | |
| JP2000239169A (en) | Promotor agent for anti-carcinogenesis | |
| CN1515294A (en) | Solid preparation containing extract of three-bristle cudrania and its preparation method | |
| CN101028262A (en) | Medicinal composition with anti-inflammatory and anti-infective functions | |
| CN1785991A (en) | Anti inflammatory detoxication luteolin kind new medicine and its preparation method | |
| CN1974603A (en) | Alpha-glucosan originated from ash tree flower sporophore and its prepn process and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: BEIJING JBC CHINESE TRADITIONAL MEDICINE SCIENCE AND TECHNOLOGY DEVELOP CO.,LTD. Document name: Notification to Pay the Fees |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20090128 |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: BEIJING JBC CHINESE TRADITIONAL MEDICINE SCIENCE AND TECHNOLOGY DEVELOP CO.,LTD. Person in charge of patentsThe principal of patent Document name: Notice of Termination of Patent Rights |